Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

计划入组 13 人 · 首次发布于 2020 年 10 月 9 日

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

计划入组 28 人 · 首次发布于 2025 年 7 月 23 日

ADH1 and ADH2 Disease Monitoring Study (DMS)

计划入组 95 人 · 首次发布于 2022 年 2 月 7 日

autosomal dominant polycystic kidney disease therapeutics

Autosomal dominant polycystic kidney disease(Maze Therapeutics)

autosomal dominant polycystic kidney disease therapy, Healx

Regulus Therapeutics

United States

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

China

Universidad Autonoma de Chile

Chile

BridgeBio Reports Positive Pipeline Progress and Q3 2024 Financial Results

BridgeBio Pharma's Acoramidis Shows Promise in Transthyretin Cardiomyopathy Trial

BridgeBio's Attruby Sees Strong Early Demand; Phase 3 Trials Fully Enrolled